



**SPECIAL BIDS AND AWARDS COMMITTEE
(SBAC)**

RESOLUTION

For FDA-SBAC- ITB No. 2021-004-ICTMD

PROCUREMENT FOR THE SUPPLY AND DELIVERY OF BRANDED MID-RANGE LAPTOP COMPUTERS (LOT A) AND BRANDED HIGH-END LAPTOP COMPUTERS (LOT B)

WHEREAS, the Food and Drug Administration (FDA) Special Bids and Awards Committee (SBAC) received a duly approved Purchase Request (PR) for the **PROCUREMENT FOR THE SUPPLY AND DELIVERY OF BRANDED MID RANGE LAPTOP COMPUTERS (LOT A) AND BRANDED HIGH-END LAPTOP COMPUTERS (LOT B)** with a total Approved Budget for the Contract (ABC) of **Forty-Eight Million Two Hundred Twenty Thousand Pesos (Php48, 220,000.00)**.

WHEREAS, the abovementioned procurement project was explicitly indicated in the approved FDA Updated Annual Procurement Plan for the Fiscal Year 2021;

WHEREAS, on 05 October 2021, a Pre-Procurement Conference was held prior to the approval of the Purchase Request. The activity was presided by the SBAC Chairperson with BAC Members, Technical Working Group (TWG), End-user and SBAC Secretariat;

WHEREAS, the documentary requirements and technical specifications were evaluated by the FDA-SBAC, discussed the modality of procurement to be adopted and examined the readiness to proceed the conduct of Public Bidding activities for the above-mentioned procurement project;

WHEREAS, the request for the amendment of the 545 units desktop computers into mid-range laptop originally included in the approved Information System Strategic Planning (ISSP) dated 27 October 2020 was asked by the SBAC Chairperson and instructed the end-user to follow up its approval;

WHEREAS, on the said conference, the SBAC Chairperson categorically mentioned that no award will be issued unless the request for amendment is approved;

WHEREAS, the FDA-SBAC posted an Invitation to Bid (ITB), FDA-SBAC-ITB No.2021-004-ICTMD which was duly published on 28 October 2021 and simultaneously posted in PHILGEPs and FDA websites as well as in a conspicuous place in the FDA compound;

WHEREAS, invitations were sent to NAMFREL, Phil. Chamber of Commerce, and FDA-Commission of Audit (COA) requesting their organization for representatives to observe the conduct of Public Bidding during the Pre-Bid Conference, Opening of Bids, Bid Evaluation and Post-Qualification proceedings. However, despite sending the notice and invitation to aforementioned observers only the representative from COA was able to attend the public bidding activities;



Handwritten signature

WHEREAS, a quorum of FDA-SBAC-Members was established in every stage of Public Bidding activities and proceedings for the above-mentioned procurement;

WHEREAS, in response to the previously mentioned advertisement in PhilGEPS Website and in the Food and Drug Administration transparency seal website as well as in a conspicuous place in the compound of the Food and Drug Administration, two (2) prospective bidders namely **ADVANCE SOLUTIONS INC AND JONECO TECH MARKETING CORP.** attended the Pre-Bid Conference on 05 November 2021 held online via Google meet;

WHEREAS, the Supplemental/Bid Bulletin was posted on 08 November 2021 in PHILGEPs and FDA websites as well as in a conspicuous place in the FDA compound showing the recommendation/amendment/addendum on the issues/concerns and other clarifications that were raised during the Pre-Bid Conference;

WHEREAS, on 23 November 2021, a Notice of Postponement was issued and posted in PHILGEPs and FDA websites as well as in a conspicuous place in the FDA compound stating that said activity is postponed due to conflict of schedule among SBAC members thus resulting to lack of quorum;

WHEREAS, copies of the Notice of Postponement were furnished to the Commission on Audit and prospective bidders;

WHEREAS, the submission, opening and bid evaluation for the above ITB was held on 25 November 2021 through online submission and online bid opening via Google meet respectively;

WHEREAS, during the submission of bids on 25 November 2021, two (2) prospective bidders participated in this procurement project namely, **COLUMBIA TECHNOLOGIES. INC. (CTI) AND JONECO TECH MARKETING CORP.;**

WHEREAS, the FDA-SBAC Chairperson instructed the SBAC Head Secretariat to open the bid proposal of the bidder who submitted first which is **COLUMBIA TECHNOLOGIES. INC. (CTI);**

WHEREAS, the SBAC Head Secretariat started by asking the representative of **COLUMBIA TECHNOLOGIES. INC. (CTI)** for the password of the first envelope, Technical Component Envelope;

WHEREAS, the FDA-SBAC conducted the preliminary and eligibility screening of the bid documents of the aforementioned bidder through **PASSED** or **FAILED** criterion using the latest checklist of technical and financial documents under the 6th edition of the Philippine Bidding Documents;

WHEREAS, the initial evaluation of the documents started with the technical components consisting of legal, technical and financial documents;

WHEREAS, during the course of bid documents evaluation, the above-mentioned bidder **PASSED** the Technical Component documents;

WHEREAS, after the opening and evaluation of the technical components' eligibility of the bid documents, the Financial Component Envelope was opened and read sequentially by the SBAC Head Secretariat. The bid price proposal of the above-mentioned prospective bidder did not exceed the Approved Budget for the Contract which is **Thirty Million Six Hundred Ninety-Nine Thousand Eight Hundred Fifty Pesos (Php 30,699,850.00)** for the **PROCUREMENT, SUPPLY AND DELIVERY OF 545 UNITS BRANDED MID-RANGE COMPUTER LAPTOP Lot A** only. Hence, the aforementioned prospective bidder **PASSED** in the financial component evaluation.

WHEREAS, next to be opened is the bid proposal of **JONECO TECH MARKETING CORP.** for the password of the first envelope, Technical Component Envelope;

WHEREAS, the FDA-SBAC conducted the preliminary and eligibility screening of the bid documents of the aforementioned bidder through **PASSED** or **FAILED** criterion using the latest checklist of technical and financial documents under the 6th edition of the Philippine Bidding Documents;

WHEREAS, following the same procedure applied in the Opening of the bid proposal of the first bidder, **JONECO TECH MARKETING CORP.**, **PASSED** both the Technical Component documents and the Financial Component Envelope, the bid price proposal of the above-mentioned prospective bidder being **Thirty Million Three Hundred Twenty-Nine Thousand Two Hundred Fifty Pesos (Php 30,329,250.00)** for the **PROCUREMENT, SUPPLY AND DELIVERY OF 545 UNITS BRANDED MID-RANGE COMPUTER LAPTOP Lot A** also, which did not exceed the Approved Budget for the Contract;

WHEREAS, both **COLUMBIA TECHNOLOGIES. INC. (CTI)** and **JONECO TECH MARKETING CORP.** submitted their bid proposal for the **PROCUREMENT, SUPPLY AND DELIVERY OF 545 UNITS BRANDED MID-RANGE COMPUTER LAPTOP Lot A** only and both **PASSED** the technical components (Envelope 1) and rendered eligible for submitting complete and accurate documents. Henceforth, the financial component envelopes of the said bidders were opened containing their respective offers, as outlined below and the bid price proposal as indicated in their bid forms was listed as read in the Abstract of Bids prepared by the SBAC Secretariat:

BIDDERS	BID AMOUNT
1. COLUMBIA TECHNOLOGIES. INC. (CTI)	Php 30, 699,850.00
2. JONECO TECH MARKETING CORP.	Php 30, 329,250.00

WHEREAS, no bidder submitted the bid proposal for the **PROCUREMENT, SUPPLY AND DELIVERY OF 194 UNITS BRANDED HIGH-END COMPUTER LAPTOP Lot B** thus this is declared **Failure of Bidding**;

WHEREAS, the FDA-SBAC Members through the Chairperson, announced that the copy of the Bid Documents by the Bidder with **LOWEST RATED BID (LRB)** for the **PROCUREMENT, SUPPLY AND DELIVERY OF 545 UNITS BRANDED MID-RANGE COMPUTER LAPTOP Lot A** will be forwarded to the TWG to conduct thorough Bid

BAC RESOLUTION
FDA-SBAC-ITB No. 2021-004-ICTMD

Evaluation and Post Qualification to determine the responsiveness of the bid proposal specifically on the compliance with the end-user's technical specifications;

WHEREAS, JONECO TECH MARKETING CORP.'s proposal after being determined as having the **LOWEST RATED BID (LRB)**, the bid documents of the same were forwarded by the FDA-SBAC Secretariat to FDA-SBAC Technical Working Group (FDA-SBAC-TWG) for validation and evaluation of bid documents and subsequent submission of Post Qualification Report;

WHEREAS, a Notice of Post-Qualification dated 27 November 2021 was issued to **JONECO TECH MARKETING CORP.** directing the same to submit post qualification documents for final validation;

WHEREAS, the FDA-SBAC-TWG submitted its Post Qualification Evaluation Report dated 01 December 2021 for the bid proposal of **JONECO TECH MARKETING CORP.** with the findings that the said bidder's proposal complied with the end-user's technical specifications for the above procurement project;

WHEREAS, FDA-SBAC convened on 09 December 2021 to discuss and carefully review the Post Qualification Report submitted by FDA-SBAC-TWG and concluded that the bid documents/proposal submitted by **JONECO TECH MARKETING CORP.** as a duly **RESPONSIVE BID;**

WHEREAS, on the same date, the FDA-SBAC unanimously declared **JONECO TECH MARKETING CORP.** as the **LOWEST CALCULATED** and **RESPONSIVE BID (LCRB)** for the **PROCUREMENT, SUPPLY AND DELIVERY OF 545 UNITS BRANDED MID-RANGE COMPUTER LAPTOP Lot A** based on the submitted Post Qualification Report by FDA-SBAC-TWG;

WHEREAS, the FDA-SBAC Chairperson again after asking the status of the amendments request in the ISSP reiterated that this project will not be awarded until the release of the approval of the request changing the original project of desktop computers to mid-range laptop computers;

WHEREAS, on 22 December 2021, the approval was released by the Department of Information and Communication Technology (DICT) stating that:

*“Given the current pandemic situation, the FDA employees have been directed to follow the WFH (Work-From-Home) Scheme. Hence, the FDA formally requests that the item in the endorsed ISSP pertaining to **Procurement of Desktop Computers** amounting to PhP 32,700,00.00 be amended to **Procurement of Laptop Computers** instead. It is noted further that this is essential to maintain the mobility of the employees to ensure the continuous service of the agency. (See attached pages of the ISSP Amendment 2021)*

It must be recalled that the objectives of existing IT harmonization frameworks Relate to the streamlined process of review, approval, monitoring and evaluation of ICT project for the alignment of ICT planning, budgeting, and spending the interoperability of related systems and sharing of databases, the viability



of national ICT expenditures, and the centralization of ICT procurement and overhead to achieve economies of scale.

With the expansive mandate and highly specialized role of the FDA to maintain an effective health products regulatory system responsive to the country's health needs and problems, this office defers to the FDA in the measures and ICT resources identified to fully perform its mandates. Thus, this Office endorses the FDA ISSP Amendments 2021.”;

WHEREAS, the SBAC made a final disposition instructing its Secretariat to prepare a Resolution recommending the award of the Contract to the HOPE;

NOW THEREFORE, We, the members of the FDA- Special Bids and Awards Committee hereby resolve as it is hereby **RESOLVED**;

1. To declare **JONECO TECH MARKETING CORP.** as the **LOWEST CALCULATED AND RESPONSIVE BID (LCRB)** for this procurement project **PROCUREMENT, SUPPLY AND DELIVERY OF 545 UNITS BRANDED MID-RANGE COMPUTER LAPTOP Lot A**; and
2. To recommend the approval of the Head of Procuring Entity (HOPE) based on the submitted bid price proposal and the foregoing findings, the Award of Contract to **JONECO TECH MARKETING CORP.** in the amount of **Thirty Million Three Hundred Twenty-Nine Thousand Two Hundred Fifty Pesos (P 30, 329,250.00)**.

RESOLVED this 23rd day of December 2021, FDA, Alabang, Muntinlupa City.


KENNETH I. DACALLOS
Member


RODERICK C. MATEO
Member

Retired
DR. CYNTHIA R. ROSUMAN
Vice-Chairperson


ATTY. KEVIN JARDINE LUCKY S. LOZANO
Member


ATTY. RONALD R. DE VEYRA, MBA, CESO II
Deputy Director General -IM
FDA-SBAC Chairperson

Approved by:


ROLANDO ENRIQUE D. DOMINGO, MD
FDA Director General

BAC RESOLUTION
FDA-SBAC-ITB No. 2021-004-ICTMD
Page | 5